Loading stock data…
$22.91+0.40 (+1.78%)
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
Arcus Biosciences, Inc. in the Healthcare sector is trading at $22.91 with a market capitalization of $3.1B. Wall Street consensus targets $40.00 (12 analysts), implying a +74.6% move over the next 12 months. The stock is currently 28% below its 52-week high of $31.73, remaining 7.7% below its 200-day moving average. On fundamentals, Piotroski 0/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $41.00M↑ | $17.00M↓ | $33.00M↑ | $26.00M↓ | $160.00M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$96.00M↑ | -$134.00M↓ | -$114.00M↑ | -$142.00M↓ | -$8.00M |
| Net Income | -$91.00M↑ | -$128.00M↓ | -$106.00M↑ | -$135.00M | $0 |
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney ca...